We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Neuropharm | LSE:NPH | London | Ordinary Share | GB00B1NPJJ01 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMNPH
RNS Number : 4716J
Neuropharm Group PLC
31 March 2010
+------------------------------------+------------------------------+
| For immediate release | 31 March 2010 |
+------------------------------------+------------------------------+
Neuropharm Group Plc
("Neuropharm" or "the Company")
Offer Update
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on
neurodevelopmental disorders, provides the following update to shareholders.
While discussions regarding a sale of one or more of the Company's pipeline
assets are continuing, Neuropharm has received confirmation from each of the
companies with which it has been in discussions that none of them is currently
considering making an offer for the Company. As a result, the Company is no
longer considered to be in an offer period for the purposes of the Takeover
Code.
As previously announced, on 10 March 2010, the Company is also making
preparations for a Members' Voluntary Liquidation of the Company.
For further information please contact:
+----------------------------------------+----------------+
| Neuropharm | + 44 (0) 1372 |
| | 371 171 |
+----------------------------------------+----------------+
| Robert Mansfield, Chief Executive | |
| Officer | |
| Graham Yeatman, Chief Financial | |
| Officer | |
+----------------------------------------+----------------+
| | |
+----------------------------------------+----------------+
| Piper Jaffray Ltd. | + 44 (0) 20 |
| | 3142 8700 |
+----------------------------------------+----------------+
| Neil Mackison, Rupert Winckler | |
+----------------------------------------+----------------+
| | |
+----------------------------------------+----------------+
| Buchanan Communications | + 44 (0) 20 |
| | 7466 5000 |
+----------------------------------------+----------------+
| Mark Court | |
+----------------------------------------+----------------+
Notes to Editors:
About Neuropharm
Neuropharm is a speciality pharmaceutical company focused on the development of
medicines for the treatment and management of neurodevelopmental disorders.
Please visit www.neuropharm.co.uk for further information.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKKKDKCBKDKNN
1 Year Neuropharm Chart |
1 Month Neuropharm Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
